Oncology
Guidelines, trial intelligence, mechanisms and education across oncology practice, from tumour-specific updates to systemic anticancer therapy evidence.
Latest Guidelines
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary tract cancer only after 1 or more prior lines of systemic treatment, making it…
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
Test for BRAF V600E mutation in patients with advanced NSCLC before considering encorafenib plus binimetinib, as this combination is only recommended for mutation-positive disease and forms…
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors
Ripretinib is recommended as an option for adults with advanced gastrointestinal stromal tumours who have received 3 or more prior kinase inhibitors – use this in…
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant pembrolizumab to improve outcomes…
EMA Reflection Paper on Extrapolation of Efficacy in Oncology
This EMA guideline addresses EMA Reflection Paper on Extrapolation of Efficacy in Oncology in Oncology. Use it to review current recommendation wording, eligibility criteria, and implementation…
2023 ESMO Clinical Practice Guidelines: Colorectal Cancer
Covers screening recommendations for average-risk and high-risk individuals • Provides guidance on diagnostic staging and pretreatment evaluation • Addresses surgical and neoadjuvant/adjuvant treatment approaches based on…
Trial Radar
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Nivolumab showed activity and tolerable side-effects in previously-treated thymic carcinoma and B3 thymoma patients.
PHASE1A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Trial of new hormone therapy GDC-9545 alone or combined with existing drugs for advanced oestrogen receptor-positive breast cancer.
PHASE1A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in…
PHASE2A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.…
Clinical News
MPs call for sunbed advertising ban to help prevent skin cancer
A cross-party parliamentary report identifies that most skin cancer cases are preventable, supporting calls for stricter regulation of…
08 May 2026University explores endometriosis and cancer link
Endometriosis affects approximately 10% of UK women and remains associated with significant morbidity including chronic pain and reduced…
03 May 2026NHS cancer jab could mean patients spend hours less in hospital
Injectable immunotherapy formulation reduces administration time from hours to minutes, potentially decreasing hospital visits and improving patient experience…
28 Apr 202611 cancers on the rise in young people – scientists find first clue why it’s happening
Early-onset cancers are increasing across 11 cancer types in younger populations, representing a clinically significant epidemiological shift requiring…
Relevant Mechanisms
BRAF/MEK Pathway — Melanoma
BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals…
MechanismBTK Inhibition — B-cell Malignancies
BTK Inhibition — B-cell Malignancies is a clinically relevant Drug Science explainer. Bruton's tyrosine kinase (BTK) is a non-receptor cytoplasmic…
MechanismCDK4/6 Inhibition — Breast Cancer
CDK4/6 Inhibition — Breast Cancer is a clinically relevant Drug Science explainer. Cell cycle progression from G1 to S phase…
MechanismEGFR Pathway
EGFR Pathway is a clinically relevant Drug Science explainer. The epidermal growth factor receptor (EGFR/ErbB1/HER1) is a transmembrane receptor tyrosine…
MechanismHER2 Signalling
HER2 Signalling is a clinically relevant Drug Science explainer. Human epidermal growth factor receptor 2 (HER2/ErbB2) is a receptor tyrosine…
CPD, Podcasts & Webinars
No specialty-tagged education live yet
Oncology education appears here when podcasts, webinars and CPD modules are tagged to this hub.
Useful starting points in Oncology
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Nivolumab showed activity and tolerable side-effects in previously-treated thymic carcinoma and B3 thymoma patients.
TrialA Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Trial of new hormone therapy GDC-9545 alone or combined with existing drugs for advanced oestrogen receptor-positive breast cancer.
TrialA Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in…
Education that still supports this area
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
WebinarJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
WebinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
Follow Oncology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Oncology
Choose guideline, trial, Drug Science and education updates for this specialty.